← board
AMLX
Amylyx Pharmaceuticals Inc.distress 1/10 · well-funded / low risk$17.38-2%today-7% from 52w high
Neurology 1
Lead: post-bariatric hypoglycemia and other rare diseases
Revenue
pre-revenue
Liquidity
$280M
Runway
2.3 yrs
Shares 1y
+25%
Price & events
+7.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.8%
1D
+2.1%
1W
+6.2%
1M
+0.3%
3M
+10.3%
6M
+107.2%
1Y
+786.7%
2Y
—
5Y
-3.8%
All
Overview
- Market Cap
- $1.93B
- Volume
- 51.97K
- 52 Week Range
- $7.64 – $18.70
- Total Shares
- 111.19M
- Float Shares
- 82.38M
- Short %
- 16.74%
- % Held by Insiders
- 7.89%
- % Held by Institutions
- 105.33%
- RVOL
- 0.03x
- Beta
- -0.20
Pipeline stages · 2 programs
Avexitide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
AMX0035
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 0 upcoming
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 5
- 2027Guided 40%regulatory submissionFiled (NDA/BLA)AMX0318 · IND filing targetedSEC 8-K
- Q3 2026Guided 70%readoutPhase 3AVEXITIDE · Topline data expectedSEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-01-08partnershipAMX0318 · AMX0318 selected as development candidate, triggering $4M milestone to GubraSEC 8-K
- 2024-12-30partnershiplong-acting GLP-1 receptor antagonist · Collaboration with Gubra A/S for early-stage development; Amylyx has option to lead development upon candidate identification.SEC 8-K
Approved drugs (1)
- RELYVRIOSODIUM PHENYLBUTYRATE2022 · Discontinued
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $24 (+40% upside) · 10 analysts
- 2026-07-20MizuhoOutperform
- 2026-06-25GuggenheimBuy
- 2026-04-28MizuhoOutperform
- 2026-03-25HC Wainwright & Co.Buy
- 2026-03-19GuggenheimBuy
- 2026-03-04HC Wainwright & Co.Buy
Competitors — post-bariatric hypoglycemia and other rare diseases
- none identified
Recent news
- 2026-07-20Mizuho raises Amylyx stock price target to $24 ahead of trial data - Investing.com UK
- 2026-07-20Mizuho raises Amylyx stock price target to $24 ahead of trial data - Investing.com
- 2026-07-20Mizuho raises Amylyx stock price target to $24 ahead of trial data - Investing.com
- 2026-07-20Mizuho Raises Price Target on Amylyx Pharmaceuticals to $24 From $21, Keeps Outperform Rating - marketscreener.com
- 2026-07-16Amylyx Pharmaceuticals (AMLX) Sharp Decline as Stock Tests Critical Support - Wyckoff Accumulation - dars.gov.et
- 2026-07-16Trade Alert: Chief Legal Officer & General Counsel Of Amylyx Pharmaceuticals Gina Mazzariello Has Sold Stock - Sahm
- 2026-07-15AMLX Q1 2026 Earnings: Wider Loss Amid Pipeline Focus, Stock Gains - Post-Earnings Drift - dars.gov.et
- 2026-07-15Trade Alert: Chief Legal Officer & General Counsel Of Amylyx Pharmaceuticals Gina Mazzariello Has Sold Stock - simplywall.st
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.